Schizophrenia: Comprehensive Mental Health Nursing Notes
Schizophrenia is a chronic psychotic disorder characterized by disturbances of thought, perception, emotion, speech, behaviour and functioning. Diagnosis requires a clinical syndrome over time and exclusion of substance-induced, mood, neurological and medical causes. It is not “split personality,” and most affected people are not violent.
Learning objectives
- Classify positive, negative, cognitive and affective symptoms.
- Conduct risk, mental-state and physical assessments.
- Plan acute, continuing and rehabilitative nursing care.
Aetiology and pathophysiology
Schizophrenia results from interaction between genetic vulnerability and neurodevelopmental, biological, psychological and social factors. Dopamine dysregulation contributes to psychosis; glutamate and other systems, brain development, obstetric complications, childhood adversity, urban stress and high-potency cannabis may influence risk. No single cause or laboratory test confirms the diagnosis.
Clinical manifestations
| Domain | Examples | Nursing assessment |
|---|---|---|
| Positive | Delusions, auditory hallucinations, disorganized speech/behaviour, catatonia | Content, distress, command hallucinations, associated risk. |
| Negative | Reduced emotional expression, avolition, alogia, anhedonia, social withdrawal | Differentiate from depression, EPS, sedation and deprivation. |
| Cognitive | Poor attention, working memory, planning and insight | Effect on medication use, self-care and work. |
| Affective | Anxiety, depression, irritability, hopelessness | Suicide risk, especially early illness and after discharge. |
Assessment and differential diagnosis
- Engage calmly; obtain patient and collateral history, timeline, function, substances, medicines, physical illness and previous treatment.
- Mental-state examination: appearance/behaviour, speech, mood/affect, thought form/content, perception, cognition, insight and judgement.
- Risk assessment: suicide/self-neglect, vulnerability, command hallucinations, aggression, dependants and access to means.
- Physical and neurological examination; baseline weight/BMI, waist, BP, glucose/HbA1c and lipids before/soon after antipsychotic initiation.
Exclude delirium, epilepsy, HIV/CNS infection, endocrine/metabolic disease, substance/medicine-induced psychosis, bipolar mania, severe depression with psychosis, PTSD, intellectual disability and culturally sanctioned beliefs.
Management
Acute phase
- Safe low-stimulation environment, therapeutic engagement, nutrition/hydration, sleep restoration and treatment of medical/substance causes.
- Antipsychotic selected collaboratively according to prior response, adverse effects, comorbidity, availability and preference. Start low, titrate, use one antipsychotic where possible and monitor response.
- Imminent danger requires trained de-escalation and the least restrictive lawful intervention. Do not argue with delusions; acknowledge distress and present reality briefly.
Continuing care and rehabilitation
- Psychoeducation, family intervention, adherence support, relapse plan, social/occupational rehabilitation and management of substance use.
- WHO recommends continuing antipsychotic treatment for at least 7–12 months after remission of a first psychotic episode, balancing effectiveness, adverse effects and preference; recurrent illness often needs longer specialist-guided treatment.
- Consider long-acting injectable medicine when preferred or useful for adherence; clozapine for treatment resistance only with specialist supervision and required blood monitoring.
Antipsychotic pharmacology
| Group | Examples/indication | Major adverse effects | Nursing monitoring |
|---|---|---|---|
| First generation | Haloperidol, chlorpromazine; acute and maintenance psychosis | EPS, tardive dyskinesia, hyperprolactinaemia, QT effects; chlorpromazine also sedation/hypotension | Movement assessment, ECG risk, BP, falls, prolactin symptoms; watch for NMS. |
| Second generation | Risperidone, olanzapine and others | Weight gain, diabetes, dyslipidaemia; risperidone prolactin/EPS; olanzapine marked metabolic risk | Weight/BMI, waist, BP, glucose and lipids; diet/activity support. |
| Clozapine | Treatment-resistant schizophrenia | Agranulocytosis, myocarditis, seizures, severe constipation/ileus, metabolic effects, hypersalivation | Mandatory blood counts, infection warning, bowel monitoring, pulse/temperature and urgent review for chest symptoms. |
Nursing care plan
| Diagnosis | Interventions with rationale/outcome |
|---|---|
| Disturbed thought processes | Use clear short statements, maintain consistency, avoid validating or arguing with delusions, gently focus on reality. Outcome: reduced distress and improved engagement. |
| Disturbed sensory perception | Assess hallucination content and commands; identify triggers; teach distraction/grounding; increase observation if dangerous. Outcome: patient seeks help before acting. |
| Self-care deficit | Assess abilities, break tasks into steps, cue rather than take over, reinforce progress. Outcome: increasing independence. |
| Social isolation | Begin one-to-one contact, introduce graded groups, teach social skills and link rehabilitation. Outcome: tolerates purposeful interaction. |
| Risk for metabolic syndrome | Baseline and scheduled monitoring, nutrition/activity counselling, communicate abnormal results. Outcome: early prevention/treatment. |
Relapse warning signs and education
- Sleep disturbance, withdrawal, suspiciousness, declining self-care, reduced adherence, irritability or return of unusual experiences.
- Create a written early-warning plan with patient/family, emergency contacts and preferred care.
- Promote rights, dignity, shared decision-making, physical health, reproductive counselling and social inclusion.
Prognosis and complications
Course varies. Early treatment, adherence, supportive family/social environment and rehabilitation improve outcomes. Complications include suicide, substance use, homelessness, victimization, physical disease, medicine adverse effects and caregiver strain.
Revision questions
- Classify symptoms of schizophrenia with examples.
- Outline baseline monitoring before antipsychotics.
- Develop a five-problem nursing care plan.
- State indications and safety monitoring for clozapine.
References
- WHO. mhGAP Guideline for Mental, Neurological and Substance Use Disorders, 2023.
- WHO. mhGAP Intervention Guide, Version 2.0.
- Uganda Ministry of Health. Uganda Clinical Guidelines, 2023.